LibiGel’s failure—on top of the Intrinsa debacle a few years ago—is surely the end of the line for the development of a formulation of testosterone for FSDD, IMO. Although “male” products will continue to be used off-label, it’s reasonable to conclude that no drug/biotech company will ever look at this application again.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.